Compare GRC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | FTRE |
|---|---|---|
| Founded | 1933 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1994 | 2023 |
| Metric | GRC | FTRE |
|---|---|---|
| Price | $61.25 | $9.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.39 |
| AVG Volume (30 Days) | 124.9K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 32.03 | N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | $682,389,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $6.62 | N/A |
| Revenue Next Year | $4.66 | $3.01 |
| P/E Ratio | $31.00 | ★ N/A |
| Revenue Growth | ★ 3.44 | 1.00 |
| 52 Week Low | $30.87 | $3.97 |
| 52 Week High | $68.02 | $18.67 |
| Indicator | GRC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 35.46 |
| Support Level | $56.98 | $8.85 |
| Resistance Level | $67.61 | $11.22 |
| Average True Range (ATR) | 2.36 | 0.57 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 51.50 | 26.11 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.